Poolbeg Pharma upbeat on preliminary influenza drug results

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.93
+3.66 (1.78%)
AAPL  273.02
+6.84 (2.57%)
AMD  211.01
+14.41 (7.33%)
BAC  50.09
-0.98 (-1.91%)
GOOG  310.89
-0.80 (-0.26%)
META  638.87
+1.62 (0.25%)
MSFT  386.31
+1.84 (0.48%)
NVDA  192.24
+0.69 (0.36%)
ORCL  144.65
+3.34 (2.36%)
TSLA  402.93
+3.10 (0.78%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.